|
Volumn 27, Issue 36, 2009, Pages
|
Clinical utility of serum human epidermal growth factor receptor 2 extracellular domain levels: Stop the shilly-shally-it is time for a well-designed, large-scale prospective study
|
Author keywords
[No Author keywords available]
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
TRASTUZUMAB;
TUMOR MARKER;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
BLOOD LEVEL;
BLOOD SAMPLING;
BREAST CANCER;
BREAST TUMOR;
CANCER THERAPY;
CLINICAL DECISION MAKING;
CLINICAL EVALUATION;
CLINICAL PRACTICE;
CONCENTRATION (PARAMETERS);
CORRELATION ANALYSIS;
DIAGNOSTIC ACCURACY;
DISEASE COURSE;
EXTRACELLULAR MATRIX;
HUMAN;
LETTER;
METASTASIS;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
SCIENTIFIC LITERATURE;
SENSITIVITY AND SPECIFICITY;
TREATMENT RESPONSE;
BLOOD;
ENZYMOLOGY;
FEMALE;
NOTE;
PROTEIN TERTIARY STRUCTURE;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
FEMALE;
HUMANS;
PROSPECTIVE STUDIES;
PROTEIN STRUCTURE, TERTIARY;
RECEPTOR, ERBB-2;
TUMOR MARKERS, BIOLOGICAL;
|
EID: 74949097805
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2009.24.5100 Document Type: Letter |
Times cited : (9)
|
References (4)
|